CD Antigen Cancer Therapy Market

CD Antigen Cancer Therapy Market - Global Industry Assessment & Forecast

Healthcare

# Pages:

197

Base Year:

2023

Jun - 2024

Format:

Report Code:

VMR-2503

Segments Covered

By Type of CD Antigen Targeted CD19, CD20, CD30, CD33, CD38, CD70, Other Types
By Therapy Type Monoclonal Antibodies (mAbs), Antibody-Drug Conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cell Therapy, Bi-specific T-cell Engagers (BiTEs), Radioimmunotherapy, Immunotoxins
By Cancer Type Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Lung Cancer, Prostate Cancer, Other Cancer Types
By End User Hospitals, Specialty Clinics, Cancer Treatment Centers, Research Institutes
By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Standard License

$ 4299 USD

Multi User License

$ 6599 USD

Enterprise License

$ 6999 USD

Snapshot

Base Year:	2023
Forecast Years:	2024 - 2032
Historical Years:	2018 - 2022
Revenue 2023:	USD 26.6 Billion
Revenue 2032:	USD 45.29 Billion
Revenue CAGR (2024 - 2032):	6.1%
Fastest Growing Region (2024 - 2032)	Asia Pacific
Largest Region (2023):	North America

Customization Offered

Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market Dynamics
Region Level Market Share
Import Export Analysis
Production Analysis
Others Request Customization Speak To Analyst

Executive Dashboard
1. Strategic Imperatives
Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Global CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Global CD Antigen Cancer Therapy Market, 2016 - 2028 (USD Million)
3. Global CD Antigen Cancer Therapy Market - by Type of CD Antigen Targeted
  1. By CD19
  2. By CD20
  3. By CD30
  4. By CD33
  5. By CD38
  6. By CD70
  7. By Other Types
4. Global CD Antigen Cancer Therapy Market - by Therapy Type
  1. By Monoclonal Antibodies (mAbs)
  2. By Antibody-Drug Conjugates (ADCs)
  3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
  4. By Bi-specific T-cell Engagers (BiTEs)
  5. By Radioimmunotherapy
  6. By Immunotoxins
5. Global CD Antigen Cancer Therapy Market - by Cancer Type
  1. By Leukemia
  2. By Lymphoma
  3. By Multiple Myeloma
  4. By Breast Cancer
  5. By Lung Cancer
  6. By Prostate Cancer
  7. By Other Cancer Types
6. Global CD Antigen Cancer Therapy Market - by End User
  1. By Hospitals
  2. By Specialty Clinics
  3. By Cancer Treatment Centers
  4. By Research Institutes
7. Global CD Antigen Cancer Therapy Market - by region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
8. Market comparative analysis
North America CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. North America CD Antigen Cancer Therapy Market, 2016 - 2028 (USD Million)
3. North America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
  1. By CD19
  2. By CD20
  3. By CD30
  4. By CD33
  5. By CD38
  6. By CD70
  7. By Other Types
4. North America CD Antigen Cancer Therapy Market, by Therapy Type
  1. By Monoclonal Antibodies (mAbs)
  2. By Antibody-Drug Conjugates (ADCs)
  3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
  4. By Bi-specific T-cell Engagers (BiTEs)
  5. By Radioimmunotherapy
  6. By Immunotoxins
5. North America CD Antigen Cancer Therapy Market, by Cancer Type
  1. By Leukemia
  2. By Lymphoma
  3. By Multiple Myeloma
  4. By Breast Cancer
  5. By Lung Cancer
  6. By Prostate Cancer
  7. By Other Cancer Types
6. North America CD Antigen Cancer Therapy Market, by End User
  1. By Hospitals
  2. By Specialty Clinics
  3. By Cancer Treatment Centers
  4. By Research Institutes
7. North America CD Antigen Cancer Therapy Market, by Country
  1. U.S.
    1. U.S. CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. U.S. CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. U.S. CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. U.S. CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  2. Canada
    1. Canada CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Canada CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Canada CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Canada CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  3. Mexico
    1. Mexico CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Mexico CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Mexico CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Mexico CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
Europe CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Europe CD Antigen Cancer Therapy Market, 2016 - 2028 (USD Million)
3. Europe CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
  1. By CD19
  2. By CD20
  3. By CD30
  4. By CD33
  5. By CD38
  6. By CD70
  7. By Other Types
4. Europe CD Antigen Cancer Therapy Market, by Therapy Type
  1. By Monoclonal Antibodies (mAbs)
  2. By Antibody-Drug Conjugates (ADCs)
  3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
  4. By Bi-specific T-cell Engagers (BiTEs)
  5. By Radioimmunotherapy
  6. By Immunotoxins
5. Europe CD Antigen Cancer Therapy Market, by Cancer Type
  1. By Leukemia
  2. By Lymphoma
  3. By Multiple Myeloma
  4. By Breast Cancer
  5. By Lung Cancer
  6. By Prostate Cancer
  7. By Other Cancer Types
6. Europe CD Antigen Cancer Therapy Market, by End User
  1. By Hospitals
  2. By Specialty Clinics
  3. By Cancer Treatment Centers
  4. By Research Institutes
7. Europe CD Antigen Cancer Therapy Market, by Country
  1. Germany
    1. Germany CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Germany CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Germany CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Germany CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  2. UK
    1. UK Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. UK Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. UK Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. UK Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  3. France
    1. France CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. France CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. France CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. France CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  4. Spain
    1. Spain CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Spain CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Spain CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Spain CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  5. Italy
    1. Italy CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Italy CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Italy CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Italy CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  6. BENELUX
    1. BENELUX CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. BENELUX CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. BENELUX CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. BENELUX CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  7. Rest of Europe
    1. Rest Of Europe CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Rest Of Europe CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Rest Of Europe CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Rest Of Europe CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
Asia Pacific CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Asia Pacific CD Antigen Cancer Therapy Market, 2016 - 2028 (USD Million)
3. Asia Pacific CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
  1. By CD19
  2. By CD20
  3. By CD30
  4. By CD33
  5. By CD38
  6. By CD70
  7. By Other Types
4. Asia Pacific CD Antigen Cancer Therapy Market, by Therapy Type
  1. By Monoclonal Antibodies (mAbs)
  2. By Antibody-Drug Conjugates (ADCs)
  3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
  4. By Bi-specific T-cell Engagers (BiTEs)
  5. By Radioimmunotherapy
  6. By Immunotoxins
5. Asia Pacific CD Antigen Cancer Therapy Market, by Cancer Type
  1. By Leukemia
  2. By Lymphoma
  3. By Multiple Myeloma
  4. By Breast Cancer
  5. By Lung Cancer
  6. By Prostate Cancer
  7. By Other Cancer Types
6. Asia Pacific CD Antigen Cancer Therapy Market, by End User
  1. By Hospitals
  2. By Specialty Clinics
  3. By Cancer Treatment Centers
  4. By Research Institutes
7. Asia Pacific CD Antigen Cancer Therapy Market, by Country
  1. China
    1. China CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. China CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. China CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. China CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  2. Japan
    1. Japan CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Japan CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Japan CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Japan CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  3. India
    1. India CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. India CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. India CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. India CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  4. South Korea
    1. South Korea CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. South Korea CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. South Korea CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. South Korea CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  5. South East Asia
    1. South East Asia CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. South East Asia CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. South East Asia CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. South East Asia CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  6. Rest of Asia Pacific
    1. Rest of Asia Pacific CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Rest of Asia Pacific CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Rest of Asia Pacific CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Rest of Asia Pacific CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
Latin America CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Latin America CD Antigen Cancer Therapy Market, 2016 - 2028 (USD Million)
3. Latin America CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
  1. By CD19
  2. By CD20
  3. By CD30
  4. By CD33
  5. By CD38
  6. By CD70
  7. By Other Types
4. Latin America CD Antigen Cancer Therapy Market, by Therapy Type
  1. By Monoclonal Antibodies (mAbs)
  2. By Antibody-Drug Conjugates (ADCs)
  3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
  4. By Bi-specific T-cell Engagers (BiTEs)
  5. By Radioimmunotherapy
  6. By Immunotoxins
5. Latin America CD Antigen Cancer Therapy Market, by Cancer Type
  1. By Leukemia
  2. By Lymphoma
  3. By Multiple Myeloma
  4. By Breast Cancer
  5. By Lung Cancer
  6. By Prostate Cancer
  7. By Other Cancer Types
6. Latin America CD Antigen Cancer Therapy Market, by End User
  1. By Hospitals
  2. By Specialty Clinics
  3. By Cancer Treatment Centers
  4. By Research Institutes
7. Latin America CD Antigen Cancer Therapy Market, by Country
  1. Brazil
    1. Brazil CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Brazil CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Brazil CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Brazil CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  2. Argentina
    1. Argentina CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Argentina CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Argentina CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Argentina CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  3. Rest of Latin America
    1. Rest of Latin America CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Rest of Latin America CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Rest of Latin America CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Rest of Latin America CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
Middle East & Africa CD Antigen Cancer Therapy Market - Segment Analysis
1. Overview
2. Middle East & Africa CD Antigen Cancer Therapy Market, 2016 - 2028 (USD Million)
3. Middle East & Africa CD Antigen Cancer Therapy Market, by Type of CD Antigen Targeted
  1. By CD19
  2. By CD20
  3. By CD30
  4. By CD33
  5. By CD38
  6. By CD70
  7. By Other Types
4. Middle East & Africa CD Antigen Cancer Therapy Market, by Therapy Type
  1. By Monoclonal Antibodies (mAbs)
  2. By Antibody-Drug Conjugates (ADCs)
  3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
  4. By Bi-specific T-cell Engagers (BiTEs)
  5. By Radioimmunotherapy
  6. By Immunotoxins
5. Middle East & Africa CD Antigen Cancer Therapy Market, by Cancer Type
  1. By Leukemia
  2. By Lymphoma
  3. By Multiple Myeloma
  4. By Breast Cancer
  5. By Lung Cancer
  6. By Prostate Cancer
  7. By Other Cancer Types
6. Middle East & Africa CD Antigen Cancer Therapy Market, by End User
  1. By Hospitals
  2. By Specialty Clinics
  3. By Cancer Treatment Centers
  4. By Research Institutes
7. Middle East & Africa CD Antigen Cancer Therapy Market, by Country
  1. GCC Countries
    1. GCC Countries CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. GCC Countries CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. GCC Countries CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. GCC Countries CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  2. South Africa
    1. South Africa CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. South Africa CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. South Africa CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. South Africa CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
  3. Rest of Middle East & Africa
    1. Rest of Middle East & Africa CD Antigen Cancer Therapy Market, By Type of CD Antigen Targeted
      1. By CD19
      2. By CD20
      3. By CD30
      4. By CD33
      5. By CD38
      6. By CD70
      7. By Other Types
    2. Rest of Middle East & Africa CD Antigen Cancer Therapy Market, By Therapy Type
      1. By Monoclonal Antibodies (mAbs)
      2. By Antibody-Drug Conjugates (ADCs)
      3. By Chimeric Antigen Receptor (CAR) T-cell Therapy
      4. By Bi-specific T-cell Engagers (BiTEs)
      5. By Radioimmunotherapy
      6. By Immunotoxins
    3. Rest of Middle East & Africa CD Antigen Cancer Therapy Market, By Cancer Type
      1. By Leukemia
      2. By Lymphoma
      3. By Multiple Myeloma
      4. By Breast Cancer
      5. By Lung Cancer
      6. By Prostate Cancer
      7. By Other Cancer Types
    4. Rest of Middle East & Africa CD Antigen Cancer Therapy Market, By End User
      1. By Hospitals
      2. By Specialty Clinics
      3. By Cancer Treatment Centers
      4. By Research Institutes
Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Marketing Stratagy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Competative Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Company Profiles
1. Merck & Co. Inc. (U.S.)
2. Johnson & Johnson Inc. (U.S.)
3. Amgen Inc. (U.S.)
4. AbbVie Inc. (U.S.)
5. Novartis AG (Switzerland)
6. Roche Holdings AG (Switzerland)
7. Bristol Myers Squibb Company (U.S.)
8. Biogen Inc. (U.S.)
9. Celgene Corp. (U.S.)
10. Genmab A/S (Denmark)
11. Immunomedics Inc. (U.S.)
12. Gilead Sciences Inc. (U.S.)
13. AstraZeneca PLC (UK)
14. Takeda Pharmaceutical Company Ltd. (Japan)
15. Seattle Genetics Inc. (U.S.)
Key Primary Respondents - VERBATIM
Discussion Guide
Customization Offered
Annexure
List of Figures
List of Tables
List of Abbreviations

Vantage Market Research | 25-Jun-2024

Amgen's IMDELLTRA™ Receives FDA Approval for Extensive-Stage Small Cell Lung Cancer Treatment

FAQ

Frequently Asked Question

What is the global demand for CD Antigen Cancer Therapy in terms of revenue?

The global CD Antigen Cancer Therapy valued at USD 26.6 Billion in 2023 and is expected to reach USD 45.29 Billion in 2032 growing at a CAGR of 6.1%.

Which are the prominent players in the market?

The prominent players in the market are Merck & Co. Inc. (U.S.), Johnson & Johnson Inc. (U.S.), Amgen Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Roche Holdings AG (Switzerland), Bristol Myers Squibb Company (U.S.), Biogen Inc. (U.S.), Celgene Corp. (U.S.), Genmab A/S (Denmark), Immunomedics Inc. (U.S.), Gilead Sciences Inc. (U.S.), AstraZeneca PLC (UK), Takeda Pharmaceutical Company Ltd. (Japan), Seattle Genetics Inc. (U.S.).

At what CAGR is the market projected to grow within the forecast period?

The market is project to grow at a CAGR of 6.1% between 2024 and 2032.

What are the driving factors fueling the growth of the market.

The driving factors of the CD Antigen Cancer Therapy include

Which region accounted for the largest share in the market?

North America was the leading regional segment of the CD Antigen Cancer Therapy in 2023.

CD Antigen Cancer Therapy Market

CD Antigen Cancer Therapy Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for CD Antigen Cancer Therapy in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Vantage Market Research

Products & Services

Media

Contact Us

CD Antigen Cancer Therapy Market

CD Antigen Cancer Therapy Market - Global Industry Assessment & Forecast

Healthcare

Segments Covered

Snapshot

Customization Offered

FAQ

Frequently Asked Question

What is the global demand for CD Antigen Cancer Therapy in terms of revenue?

Which are the prominent players in the market?

At what CAGR is the market projected to grow within the forecast period?

What are the driving factors fueling the growth of the market.

Which region accounted for the largest share in the market?

Related Reports

Request Sample Report for CD Antigen Cancer Therapy Market

Vantage Point Interactive Dashboard